Articles

Breast cancer and long-term employment: A retrospective cohort study from Norway

Roy A Nielsen, Eliva Atieno Ambugo, Steffen Torp, et al. J Public Health Res. 2026 Jan 26;15(1):22799036251410249

Breast cancer and its treatment may contribute to an increased risk of unemployment, influenced by both disease-related factors and socioeconomic determinant. This retrospective study investigated long-term employment among breast cancer survivors (BCS) and assessed disease specific and socioeconomic factors assoc... Read More

13 May, 2026

Breast cancer-related mortality in Central and Eastern Europe: years of life lost and productivity costs

Goran Bencina, Nour Chami, Robert Hughes, et al. J Med Econ. 2023 Jan-Dec;26(1):254-261

Breast cancer (BC) poses a public health challenge as the most commonly diagnosed cancer among women globally. While BC mortality has declined across Europe in the past three decades, an opposite trend has been reported in some transitional European countries. The human capital approach (HCA) was used to estimate ... Read More

13 May, 2026

The productivity cost of mortality due to lung cancer, breast cancer and melanoma in Europe across 2010, 2015 and 2019

Agnes Brandtmüller, Anne Meiwald, Edward Oliver, et al. J Cancer Policy. 2024 Dec:42:100499

Cancer caused an estimated 2.2 million deaths across Europe in 2020. This analysis estimated the cost of lost productivity due to premature deaths associated with lung, breast and melanoma cancer and investigated the temporal trends across European regions across 2010, 2015 and 2019. The number of cancer deaths re... Read More

13 May, 2026

Medications to reduce breast cancer risk: a network meta-analysis of randomized controlled trials

Ghazaleh Pourali, Minglu Liu, Supriya S Sherpa, et al. Breast Cancer Res. 2025 Jul 1;27(1):118

Given the rising incidence of breast cancer, especially in premenopausal women, there is an urgent need to identify additional risk-reducing medications to accelerate prevention, as only a few are currently approved. Out of 8,598 studies screened, 43 RCTs (n = 337,240 women) met inclusion criteria. Six medications... Read More

13 May, 2026

Lifestyle changes and risk of cancer: experience from the Swedish women's lifestyle and health cohort study

Edoardo Botteri, Paula Berstad, Sven Sandin, Elisabete Weiderpass. Acta Oncol. 2021 Jul;60(7):827-834

We investigated this issue in the Swedish Women's Lifestyle and Health Cohort Study. We included 29,930 women. From 1991/92 to 2003, median age changed from 40.0 to 51.7 years, alcohol consumption from 2.5 to 4.7 grams/day, BMI from 22.7 to 24.5 kg/m2, proportion of current smokers from 31.0 to 20.6% and women repo... Read More

13 May, 2026

Healthy Lifestyle and Cancer Risk: Modifiable Risk Factors to Prevent Cancer

Pasquale Marino, Mariangela Mininni, Giovanni Deiana, et al. Nutrients. 2024 Mar 11;16(6):800

Cancer has become a serious problem worldwide, as it represents the main cause of death, and its incidence has increased over the years. A potential strategy to counter the growing spread of various forms of cancer is the adoption of prevention strategies, particularly the use of healthy lifestyles, such as maintai... Read More

13 May, 2026

De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial

Xiu-Chun Chen, De-Chuang Jiao, Jiang-Hua Qiao, et al. Lancet Oncol. 2025 Jan;26(1):27-36

We aimed to evaluate the efficacy of weekly nab-paclitaxel compared with the standard regimen of docetaxel plus carboplatin, both with trastuzumab and pertuzumab, as neoadjuvant therapies for patients with HER2-positive breast cancer. Between Sept 20, 2020, and March 1, 2023, 689 eligible patients were randomly as... Read More

13 May, 2026

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Peter Schmid, Javier Cortes, Rebecca Dent, et al. N Engl J Med. 2024 Nov 28;391(21):1981-1991

In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing chemotherapy. Here we report the final results for overall survival. chemothe... Read More

13 May, 2026

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial

Fatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, et al. Nat Med. 2025 Feb;31(2):442-448

We conducted a double-blind, placebo-controlled phase 3 study (KEYNOTE-756) in which patients with previously untreated ER+/HER2-grade 3 high-risk invasive breast cancer (T1c-2 (≥2 cm), cN1-2 or T3-4, cN0-2) were randomly assigned (1:1) to neoadjuvant pembrolizumab 200 mg or placebo Q3W given with paclitaxel QW for... Read More

13 May, 2026

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial

Sherene Loi, Roberto Salgado, Giuseppe Curigliano, et al. Nat Med. 2025 Feb;31(2):433-441

We conducted a randomized, multicenter, double-blind phase 3 trial to investigate the benefit of adding nivolumab to neoadjuvant chemotherapy in patients with newly diagnosed, high-risk, grade 3 or 2 (ER 1 to ≤10%) ER+/HER2- primary BC. In total, 510 patients were randomized to receive anthracycline and taxane-base... Read More

13 May, 2026